论文部分内容阅读
目的 :研究体外构建的HSP70 肝癌抗原肽复合物诱导针对肝癌的特异性免疫反应能力 ,为该复合物的临床应用奠定基础。方法 :在体外构建HSP70 肝癌抗原肽复合物 ,联合应用粒 /巨细胞集落刺激因子 (GM CSF)及白介素 4 (IL 4 )直接从志愿者外周血中培养出DC ;以HSP70、HSP70 肝癌抗原肽、抗原肽分别刺激DC ,DC激活同源的T淋巴细胞产生细胞毒性T淋巴细胞 (CTL) ,检测其杀伤T2细胞和肝癌细胞系的能力。结果 :HSP70 抗原肽、抗原肽均可诱导CD8+的抗原肽特异性CTL ,而前者的诱导效果更强。结论 :体外构建的HSP70 抗原肽复合物具有免疫原性 ,HSP70可以增强抗原肽诱导特异性免疫反应的能力 ,HSP70 抗原肽复合物有可能作为肽疫苗用于临床肿瘤免疫治疗
Objective : To study the ability of HSP70 hepatocarcinoma antigen peptide complexes constructed in vitro to induce specific immune response against liver cancer and lay a foundation for the clinical application of the compound. METHODS: HSP70 hepatocarcinoma antigen peptide complexes were constructed in vitro. DCs were directly cultured from peripheral blood of volunteers using granulocyte colony-stimulating factor (GM CSF) and interleukin 4 (IL 4); HSP70 and HSP70 hepatocarcinoma antigen peptides were used. The antigen peptides stimulated DCs, and DCs activated homologous T lymphocytes to produce cytotoxic T lymphocytes (CTLs) and tested their ability to kill T2 cells and hepatoma cell lines. Results: HSP70 antigen peptides and antigen peptides all induced CD8+ antigen peptide-specific CTLs, and the former had stronger induction effect. Conclusion: The in vitro constructed HSP70 antigen peptide complex is immunogenic and HSP70 can enhance the ability of antigen peptide to induce specific immune response. HSP70 antigen peptide complex may be used as a peptide vaccine for clinical tumor immunotherapy.